Articles by Mathini Ilancheran
-
Global Implications Of Zero Tariffs On Indian Pharma Exports To China
11/5/2025
Discover the worldwide impacts of China’s zero-tariff policy on Indian pharmaceutical drugs.
-
100% U.S. Drug Tariffs: Implications For Pharma And Outsourcing
10/17/2025
Research Manager Mathini Ilancheran explores the effects of U.S. drug tariffs on global supply chains, multinational pharma firms, and critical partners across drug development.
-
India's New Drugs, Medical Devices, And Cosmetics Draft Bill 2022
11/7/2022
To accommodate changing requirements and encourage the adoption of new technology, India’s Ministry of Health and Family Welfare released a draft bill in July 2022 to replace the existing Drugs and Cosmetics Act 1940. What are the major areas of change and how much of an impact will there be?
-
COVID-19's Impact On Availability Of Drugs And API From India And China
4/23/2020
COVID-19 has caused an increase in demand for APIs and drugs; those used as antimalarials are seeing the highest demand, followed by bronchodilators, antibiotics, and antivirals. This article reviews the drugs and API in demand globally, with assessments of their supply status in India and China.
-
COVID-19, Medical Drones, & The Last Mile Of The Pharma Supply Chain
4/6/2020
During crises like this pandemic, bottlenecks in drug distribution and sample testing can be improved through automation, artificial intelligence, and robotics. This article provides an overview of the medical drone industry, with a particular emphasis on its adoption by the pharmaceutical sector to solve logistical problems in healthcare during times of heightened need.